PCM
RAPT

Pentwater Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Pentwater Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,250
Closed -$198K – 375
2020
Q4 		$198K Buy
+1,250
New +$272K ﹤0.01% 228

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pentwater Capital Management's RAPT Position: Q1 2023 in Review

Pentwater Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 3,125 shares — an estimated $495K sold.

Pentwater Capital Management first reported a position in RAPT in Q1 2020 and held it in 9 quarters. The position peaked at $4.22M in Q4 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

  • Pentwater Capital Management reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pentwater Capital Management sold 3,125 RAPT Therapeutics shares in Q1 2023, an estimated $495K.
  • Pentwater Capital Management first reported a position in RAPT Therapeutics in Q1 2020 and held it in 9 quarters.
  • Pentwater Capital Management's RAPT Therapeutics position peaked at $4.22M in Q4 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Pentwater Capital Management's 13F filing for Q1 2023, filed 15 May 2023.